Measures of Longitudinal Immune Dysfunction and Risk of AIDS and Non-AIDS Defining Malignancies in Antiretroviral-Treated People With Human Immunodeficiency Virus
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Measures of Longitudinal Immune Dysfunction and Risk of AIDS and Non-AIDS Defining Malignancies in Antiretroviral-Treated People With Human Immunodeficiency Virus. / Chammartin, Frédérique; Mocroft, Amanda; Egle, Alexander; Zangerle, Robert; Smith, Colette; Mussini, Cristina; Wit, Ferdinand; Vehreschild, Jörg Janne; d’Arminio Monforte, A.; Castagna, Antonella; Bailly, Laurent; Bogner, Johannes; de Wit, Stéphane; Matulionyte, Raimonda; Law, Matthew; Svedhem, Veronica; Tallada, Joan; Garges, Harmony P.; Marongiu, Andrea; Borges, Álvaro H.; Jaschinski, Nadine; Neesgaard, Bastian; Ryom, Lene; Bucher, Heiner C.; RESPOND Study Group.
In: Clinical Infectious Diseases, Vol. 78, No. 4, 2024, p. 995-1004.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Measures of Longitudinal Immune Dysfunction and Risk of AIDS and Non-AIDS Defining Malignancies in Antiretroviral-Treated People With Human Immunodeficiency Virus
AU - Chammartin, Frédérique
AU - Mocroft, Amanda
AU - Egle, Alexander
AU - Zangerle, Robert
AU - Smith, Colette
AU - Mussini, Cristina
AU - Wit, Ferdinand
AU - Vehreschild, Jörg Janne
AU - d’Arminio Monforte, A.
AU - Castagna, Antonella
AU - Bailly, Laurent
AU - Bogner, Johannes
AU - de Wit, Stéphane
AU - Matulionyte, Raimonda
AU - Law, Matthew
AU - Svedhem, Veronica
AU - Tallada, Joan
AU - Garges, Harmony P.
AU - Marongiu, Andrea
AU - Borges, Álvaro H.
AU - Jaschinski, Nadine
AU - Neesgaard, Bastian
AU - Ryom, Lene
AU - Bucher, Heiner C.
AU - RESPOND Study Group
N1 - Publisher Copyright: © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
PY - 2024
Y1 - 2024
N2 - Background. Human immunodeficiency virus (HIV) infection leads to chronic immune activation/inflammation that can persist in virally suppressed persons on fully active antiretroviral therapy (ART) and increase risk of malignancies. The prognostic role of low CD4:CD8 ratio and elevated CD8 cell counts on the risk of cancer remains unclear. Methods. We investigated the association of CD4:CD8 ratio on the hazard of non-AIDS defining malignancy (NADM), AIDS-defining malignancy (ADM) and most frequent group of cancers in ART-treated people with HIV (PWH) with a CD4 and CD8 cell counts and viral load measurements at baseline. We developed Cox proportional hazard models with adjustment for known confounders of cancer risk and time-dependent cumulative and lagged exposures of CD4:CD8 ratio to account for time-evolving risk factors and avoid reverse causality. Results. CD4:CD8 ratios below 0.5, compared to above 1.0, were independently associated with a 12-month time-lagged higher risk of ADM and infection-related malignancies (adjusted hazard ratio 2.61 [95% confidence interval {CI }1.10–6.19] and 2.03 [95% CI 1.24–3.33], respectively). CD4 cell counts below 350 cells/μL were associated with an increased risk of NADMs and ADMs, as did infection, smoking, and body mass index-related malignancies. Conclusions. In ART-treated PWH low CD4:CD8 ratios were associated with ADM and infection-related cancers independently from CD4 and CD8 cell counts and may alert clinicians for cancer screening and prevention of NADM.
AB - Background. Human immunodeficiency virus (HIV) infection leads to chronic immune activation/inflammation that can persist in virally suppressed persons on fully active antiretroviral therapy (ART) and increase risk of malignancies. The prognostic role of low CD4:CD8 ratio and elevated CD8 cell counts on the risk of cancer remains unclear. Methods. We investigated the association of CD4:CD8 ratio on the hazard of non-AIDS defining malignancy (NADM), AIDS-defining malignancy (ADM) and most frequent group of cancers in ART-treated people with HIV (PWH) with a CD4 and CD8 cell counts and viral load measurements at baseline. We developed Cox proportional hazard models with adjustment for known confounders of cancer risk and time-dependent cumulative and lagged exposures of CD4:CD8 ratio to account for time-evolving risk factors and avoid reverse causality. Results. CD4:CD8 ratios below 0.5, compared to above 1.0, were independently associated with a 12-month time-lagged higher risk of ADM and infection-related malignancies (adjusted hazard ratio 2.61 [95% confidence interval {CI }1.10–6.19] and 2.03 [95% CI 1.24–3.33], respectively). CD4 cell counts below 350 cells/μL were associated with an increased risk of NADMs and ADMs, as did infection, smoking, and body mass index-related malignancies. Conclusions. In ART-treated PWH low CD4:CD8 ratios were associated with ADM and infection-related cancers independently from CD4 and CD8 cell counts and may alert clinicians for cancer screening and prevention of NADM.
KW - antiretroviral therapy
KW - CD4:CD8 ratio
KW - HIV infection
KW - malignancy
KW - observational study
U2 - 10.1093/cid/ciad671
DO - 10.1093/cid/ciad671
M3 - Journal article
C2 - 38092042
AN - SCOPUS:85190154853
VL - 78
SP - 995
EP - 1004
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
SN - 1058-4838
IS - 4
ER -
ID: 396792787